US 12,168,001 B2
Use of L-ergothioneine to ameliorate and prevent age-related vitreous degeneration
Ronghua Yi, Nanjing (CN); Qiru Fan, Nanjing (CN); Mingru Wang, Nanjing (CN); Ou Wang, Nanjing (CN); and Kylin Liao, Nanjing (CN)
Assigned to NANJING NUTRABUILDING BIO-TECH CO., LTD., Nanjing (CN)
Filed by NANJING NUTRABUILDING BIO-TECH CO., LTD., Nanjing (CN)
Filed on Dec. 20, 2023, as Appl. No. 18/391,360.
Application 18/391,360 is a continuation of application No. PCT/CN2022/100005, filed on Jun. 21, 2022.
Claims priority of application No. PCT/CN2021/101508 (WO), filed on Jun. 22, 2021.
Prior Publication US 2024/0122900 A1, Apr. 18, 2024
Int. Cl. A61K 31/4172 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/4172 (2013.01) [A61P 27/02 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method for alleviating and preventing age-associated vitreous degeneration in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-ergothioneine, or an analog thereof, or a pharmaceutically acceptable salt, acid, ester, polymer, or an analog thereof, as an active ingredient, wherein L-ergothioneine is administrated in the form of eyedrops or spongarion, and the administration of L-ergothioneine is capable of scavenging chronic reactive oxygen species directly and radically to mitigate and prevent HA depolymerization and HA decreasing-viscosity in the mammal's vitreous body, resulting in an increased vitreous gel content in a mammal's eye.